Market capitalization | $3.67b |
Enterprise Value | $3.57b |
P/E (TTM) P/E ratio | 39.54 |
EV/FCF (TTM) EV/FCF | 52.63 |
EV/Sales (TTM) EV/Sales | 10.29 |
P/S ratio (TTM) P/S ratio | 10.60 |
P/B ratio (TTM) P/B ratio | 20.69 |
Revenue growth (TTM) Revenue growth | 1,341.63% |
Revenue (TTM) Revenue | $346.73m |
As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.
9 Analysts have issued a TG Therapeutics, Inc. forecast:
9 Analysts have issued a TG Therapeutics, Inc. forecast:
Dec '23 |
+/-
%
|
||
Revenue | 234 234 |
8,275%
8,275%
|
|
Gross Profit | 219 219 |
10,801%
10,801%
|
|
EBITDA | 21 21 |
111%
111%
|
EBIT (Operating Income) EBIT | 21 21 |
111%
111%
|
Net Profit | 13 13 |
106%
106%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.
Head office | United States |
CEO | Michael Weiss |
Employees | 264 |
Founded | 1993 |
Website | www.tgtherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.